Pricing Log in Create free account
Friday 6 November 2026 Export ZYME’s income statement to Excel — free account

Zymeworks Inc.

ZYME Healthcare Biotechnology

Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.

Revenue
−90.6%
EPS
−2,166.7%
Free cash flow
−385.5%

Quarter to June 2026, against a year earlier

29.60 0.86 +2.99%
Market cap
$2.0B
P/E
0.0×
Fwd P/E
26.0×
Dividend yield
—
F-score
7/9
Altman Z
11.56
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Zymeworks Inc. (ZYME) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Zymeworks Inc. (ZYME) trades at a EV/Sales of 49.5×. Over the past ten years it has ranged from 0.1× (January 2023) to 92.8× (December 2020); the current reading is higher than 90% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 16.6× 39.46%
FY2024 11.9× 148.95%
FY2023 4.8× 8,063.25%
FY2022 0.1× (99.75%)
FY2021 23.4× (53.58%)
FY2020 50.3× 3.62%
FY2019 48.6× 1,013.08%
FY2018 4.4× 165.07%
FY2017 1.6× (87.88%)
FY2016 13.6× 0.00%

Quarterly newest first

Period EV/Sales Change
Jun 2026 44.1× 138.13%
Mar 2026 18.5× 11.72%
Dec 2025 16.6× 109.42%
Sep 2025 7.9× 41.67%
38 more quarters

Against its own ten years

Low 0.1× High 92.8×
Ten-year median 9.4×
Current reading's percentile 90

EV/Sales against peers

Company EV/Sales
LKFT Lakefront Biotherapeutics - Sponsored ADR compare −1.3×
COAG Hemab Therapeutics Holdings, Inc. compare n/m
VERA Vera Therapeutics, Inc. compare n/m
BHVN Biohaven Ltd. compare 2.2×
AUPH Aurinia Pharmaceuticals Inc compare 5.3×
VCEL Vericel Corporation compare 7.6×
SEPN Septerna, Inc. compare 18.1×
ZYME Zymeworks Inc. 49.5×
IMNM Immunome, Inc. compare 121×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ZYME